Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS

Propanc Biopharma Announces 1-for-10 Reverse Stock Split

Propanc Biopharma, Inc. has approved a 1-for-10 reverse stock split of its common stock, effective as of the market open on October 26, 2026, to maintain compliance with Nasdaq listing standards.

Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer

Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,

Propanc Biopharma Says Published Pilot Study Showed 85.9% Mean Tumor Weight Reduction With PRP In Pancreatic Cancer Animal Model

Propanc Biopharma Says PRP Shows Over 90% Tumor Growth Inhibition In Animal Models Of Pancreatic Cancer